What is NeuViVa and How Does it Work?
NeuViVa is the latest FDA-approved intravaginal laser for the treatment of vaginal atrophy, often now called genitourinary syndrome of menopause (GSM). Some 50% of post-menopausal women have some degree of GSM, caused by the decrease in their estrogen production. Many more women suffer from this condition as a result of having undergone a hysterectomy or breast cancer treatment. Symptoms of GSM range from mild to severe and include vaginal burning, dryness and itching, urinary incontinence, pain during intercourse, lax vaginal muscles, and chronic urinary tract infections. NeuViVa utilizes fractional CO2 laser technology to improve blood circulation and stimulate collagen production that thickens vaginal tissue. In doing so, NeuViVa offers a non-pharmaceutical remedy for women, many of whom haven’t found estrogen therapy effective. Others, such as cancer patients and women who are breastfeeding, are unable to use estrogen therapy. In fact, the system was originally designed to remedy vaginal atrophy in women who had undergone breast cancer treatment.
What Does the Procedure Entail?
Dr. Thomas has extensive experience in providing NeuViva and teaches other physicians how to perform the procedure. Treatment is minimally invasive, pain-free and administered in the office without the use of anesthesia. Dr. Thomas inserts the NeuViVa probe into the vaginal canal, where it pulses energy throughout the area. The entire procedure takes just 5-10 minutes. Patients should refrain from sex for a few days following the procedure but can resume other daily activities immediately.
What Results Can I Expect?
Most women experience some immediate reduction in such symptoms as vaginal dryness, itching, burning, and pain during intercourse. But optimum benefits require three follow-up treatments, scheduled several weeks apart. Improvement continues to increase for about five months following treatment. After that, patients undergo one annual treatment to maintain benefits. Some 90% of women using the NeuViVa systems report a substantial improvement in their symptoms.